Biologics for the treatment of adult-onset still’s disease

References

• Gerfaud-Valentin M, Jamilloux Y, Iwaz J, et al. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708–722.
   PubMed Web of Science ®Google Scholar
• Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47:6–14.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33:305–314.
   PubMed Web of Science ®Google Scholar
• Lenert A, Yao Q. Macrophage activation syndrome complicating adult onset Still’s disease: A single center case series and comparison with literature. Semin Arthritis Rheum. 2016;45:711–716.
   PubMed Web of Science ®Google Scholar
• Asanuma YF, Mimura T, Tsuboi H, et al. Nationwide epidemiological survey of 169 patients with adult Still’s disease in Japan. Mod Rheumatol. 2015;25:393–400.
   PubMed Web of Science ®Google Scholar
• Iliou C, Papagoras C, Tsifetaki N, et al. Adult-onset Still’s disease: clinical, serological and therapeutic considerations. Clin Exp Rheumatol. 2013;31:47–52.
   PubMed Web of Science ®Google Scholar
• Kalyoncu U, Solmaz D, Emmungil H, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still’s disease: Data from a large multicenter cohort. J Autoimmun. 2016;69:59–63.
   PubMed Web of Science ®Google Scholar
• Mahroum N, Mahagna H, Amital H. Diagnosis and classification of adult Still’s disease. J Autoimmun. 2014;48-49:34–37.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91–99.
   PubMed Web of Science ®Google Scholar
• Nirmala N, Brachat A, Feist E, et al. Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13:50.
   PubMed Web of Science ®Google Scholar
• Inoue N, Shimizu M, Tsunoda S, et al. Cytokine profile in adult-onset Still’s disease: Comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016;169:8–13.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61:53–62.
   PubMed Web of Science ®Google Scholar
• Pay S, Turkcapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25:639–644.
   PubMed Web of Science ®Google Scholar
• Miller ML, Aaron S, Jackson J, et al. HLA gene frequencies in children and adults with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. 1985;28:146–150.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. Ann Rheum Dis. 2013;72:627–628.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75:1654–1660.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 2008;58:2432–2442.
   PubMed Web of Science ®Google Scholar
• Quartier P. Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome. Open Access Rheumatol. 2011;3:9–18.
   PubMedGoogle Scholar
• Santos MJ, Melo-Gomes JA, Fonseca JE, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. RMD Open. 2016;1:e86336.
   Google Scholar
• Yu JR, Leslie KS. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep. 2011;11:12–20.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013;72:482–492.
   PubMed Web of Science ®Google Scholar
• Al-Homood IA. Biologic treatments for adult-onset Still’s disease. Rheumatology (Oxford). 2014;53:32–38.
   PubMed Web of Science ®Google Scholar
• Castaneda S, Blanco R, Gonzalez-Gay MA. Adult-onset Still’s disease: Advances in the treatment. Best Pract Res Clin Rheumatol. 2016;30:222–238.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Franchini S, Aiello P, et al. Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol. 2015;44:309–314.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Tomelleri A, De Luca G, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther. 2019;21:54.
   PubMed Web of Science ®Google Scholar
• Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum. 2010;62:2530–2535.
   PubMed Web of Science ®Google Scholar
• Fujii T, Akizuki M, Kameda H, et al. Methotrexate treatment in patients with adult onset Still’s disease–retrospective study of 13 Japanese cases. Ann Rheum Dis. 1997;56:144–148.
   PubMed Web of Science ®Google Scholar
• Manger B, Rech J, Schett G. Use of methotrexate in adult-onset Still’s disease. Clin Exp Rheumatol. 2010;28:S168–171.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Gerfaud-Valentin M, Henry T, et al. Treatment of adult-onset Still’s disease: a review. Ther Clin Risk Manag. 2015;11:33–43.
   PubMed Web of Science ®Google Scholar
• Weatherald J, Lategan J, Helmersen D. Pulmonary arterial hypertension secondary to adult-onset Still’s disease: Response to cyclosporine and sildenafil over 15 years of follow-up. Respir Med Case Rep. 2016;19:27–30.
   PubMed Web of Science ®Google Scholar
• Sayarlioglu M, Ucmak H, Ozkaya M, et al. Leflunomide and methotrexate combination in refractory adult-onset Still’s disease. Ann Pharmacother. 2007;41:1319–1320.
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Lan JL, et al. Potential role of Th17 cells in the pathogenesis of adult-onset Still’s disease. Rheumatology (Oxford). 2010;49:2305–2312.
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease. Ann Rheum Dis. 2004;63:1300–1306.
   PubMed Web of Science ®Google Scholar
• Choi JH, Suh CH, Lee YM, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30:2422–2427.
   PubMed Web of Science ®Google Scholar
• Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology (Oxford). 2016;55:2237–2247.
   PubMed Web of Science ®Google Scholar
• Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13:1149–1159.
   PubMed Web of Science ®Google Scholar
• Castaneda S, Atienza-Mateo B, Martin-Varillas JL, et al. Anakinra for the treatment of adult-onset Still’s disease. Expert Rev Clin Immunol. 2018;14:979–992.
   PubMed Web of Science ®Google Scholar
• Castaneda S, Martinez-Quintanilla D, Martin-Varillas JL, et al. Tocilizumab for the treatment of adult-onset Still’s disease. Expert Opin Biol Ther. 2019;19:273–286.
   PubMed Web of Science ®Google Scholar
• Mimura T, Kondo Y, Ohta A, et al. Evidence-based clinical practice guideline for adult Still’s disease. Mod Rheumatol. 2018;28:736–757.
   PubMed Web of Science ®Google Scholar
• Vercruysse F, Barnetche T, Lazaro E, et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther. 2019;21:53.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77:1720–1729.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118–136.
   PubMed Web of Science ®Google Scholar
• Rau M, Schiller M, Krienke S, et al. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol. 2010;37:2369–2376.
   PubMed Web of Science ®Google Scholar
• Mehta B, Efthimiou P. Ferritin in adult-onset still’s disease: just a useful innocent bystander? Int J Inflam. 2012;2012:298405.
   PubMedGoogle Scholar
• Jung KH, Kim JJ, Lee JS, et al. Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still’s disease. Scand J Rheumatol. 2014;43:162–169.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ciccia F, Cipriani P, et al. The CD68(+)/H-ferritin(+) cells colonize the lymph nodes of the patients with adult onset Still’s disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for pathogenesis. Clin Exp Immunol. 2016;183:397–404.
   PubMed Web of Science ®Google Scholar
• Shaikh MM, Hermans LE, van Laar JM. Is serum procalcitonin measurement a useful addition to a rheumatologist’s repertoire? A review of its diagnostic role in systemic inflammatory diseases and joint infections. Rheumatology (Oxford). 2015;54:231–240.
   PubMed Web of Science ®Google Scholar
• Bae CB, Suh CH, An JM, et al. Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still’s disease. J Rheumatol. 2014;41:2403–2408.
   PubMed Web of Science ®Google Scholar
• Wakabayashi K, Inokuma S, Matsubara E, et al. Serum beta2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still’s disease. Clin Rheumatol. 2013;32:999–1005.
   PubMed Web of Science ®Google Scholar
• Jung JY, Suh CH, Sohn S, et al. Elevated high-mobility group B1 levels in active adult-onset Still’s disease associated with systemic score and skin rash. Clin Rheumatol. 2016;35:1937–1942.
   PubMed Web of Science ®Google Scholar
• Han JH, Suh CH, Jung JY, et al. Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still’s disease. Arthritis Res Ther. 2015;17:260.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Kubota K, Mimori A. Clinical value of whole-body PET/CT in patients with active rheumatic diseases. Arthritis Res Ther. 2014;16:423.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Alessandri C, et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res. 2014;60:177–183.
   PubMed Web of Science ®Google Scholar
• Komiya A, Matsui T, Nogi S, et al. Neutrophil CD64 is upregulated in patients with active adult-onset Still’s disease. Scand J Rheumatol. 2012;41:156–158.
   Web of Science ®Google Scholar
• Kalyoncu U, Buyukasik Y, Akdogan A, et al. Increased serum vitamin B12 levels are associated with adult-onset Still’s disease with reactive macrophage activation syndrome. Joint Bone Spine. 2010;77:131–134.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Valesini G. Presentation and diagnosis of adult-onset Still’s disease: the implications of current and emerging markers in overcoming the diagnostic challenge. Expert Rev Clin Immunol. 2015;11:749–761.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuan F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of Anakinra in Refractory Adult-Onset Still’s Disease: Multicenter Study of 41 Patients and Literature Review. Medicine (Baltimore). 2015;94:e1554.
   PubMed Web of Science ®Google Scholar
• Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–308.
   PubMed Web of Science ®Google Scholar
• Giampietro C, Ridene M, Lequerre T, et al. Cri: Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65:822–826.
   PubMed Web of Science ®Google Scholar
• Priori R, Ceccarelli F, Barone F, et al. Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still’s disease. Clin Exp Rheumatol. 2008;26:933–937.
   PubMed Web of Science ®Google Scholar
• Nishina N, Kaneko Y, Kameda H, et al. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: A retrospective, single-center study. Mod Rheumatol. 2015;25:401–404.
   PubMed Web of Science ®Google Scholar
• Song ST, Kim JJ, Lee S, et al. Efficacy of tocilizumab therapy in Korean patients with adult-onset Still’s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol. 2016;34(Suppl 102):64–71.
   Google Scholar
• de Boysson H, Fevrier J, Nicolle A, et al. Tocilizumab in the treatment of the adult-onset Still’s disease: current clinical evidence. Clin Rheumatol. 2013;32:141–147.
   PubMed Web of Science ®Google Scholar
• Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol. 2014;33:49–55.
   PubMed Web of Science ®Google Scholar
• Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther. 2011;13:R91.
   PubMed Web of Science ®Google Scholar
• Li S, Lu A, Li B, et al. Circadian rhythms on hypothalamic-pituitary-adrenal axis hormones and cytokines of collagen induced arthritis in rats. J Autoimmun. 2004;22:277–285.
   PubMed Web of Science ®Google Scholar
• Bruck N, Schnabel A, Hedrich CM. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol. 2015;159:72–83.
   PubMed Web of Science ®Google Scholar
• Pathak S, McDermott MF, Savic S. Autoinflammatory diseases: update on classification diagnosis and management. J Clin Pathol. 2017;70:1–8.
   PubMed Web of Science ®Google Scholar
• Sag E, Bilginer Y, Ozen S. Autoinflammatory Diseases with Periodic Fevers. Curr Rheumatol Rep. 2017;19:41.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–430.
   PubMed Web of Science ®Google Scholar
• Masson C, Le Loet X, Liote F, et al. Comparative study of 6 types of criteria in adult Still’s disease. J Rheumatol. 1996;23:495–497.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore). 2002;81:194–200.
   PubMed Web of Science ®Google Scholar
• Sfriso P, Bindoli S, Galozzi P. Adult-onset Still’s disease: molecular pathophysiology and therapeutic advances. Drugs. 2018;78:1187–1195.
   PubMed Web of Science ®Google Scholar
• Rosario C, Zandman-Goddard G, Meyron-Holtz EG, et al. The hyperferritinemic syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185.
   PubMed Web of Science ®Google Scholar
• Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14:603–618.
   PubMed Web of Science ®Google Scholar
• Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol. 2014;66:2297–2307.
   PubMed Web of Science ®Google Scholar
• Cifaldi L, Prencipe G, Caiello I, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015;67:3037–3046.
   PubMed Web of Science ®Google Scholar
• Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol. 2010;37:967–973.
   PubMed Web of Science ®Google Scholar
• Park JH, Kim HS, Lee JS, et al. Natural killer cell cytolytic function in Korean patients with adult-onset Still’s disease. J Rheumatol. 2012;39:2000–2007.
   PubMed Web of Science ®Google Scholar
• Wada T, Kanegane H, Ohta K, et al. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine. 2014;65:74–78.
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS, Wong RW. Clinical characteristics, treatment, and outcome of adult onset Still’s disease in southern Chinese. J Rheumatol. 1998;25:2345–2351.
   PubMed Web of Science ®Google Scholar
• National Health Service England, Clinical Commissioning Policy: Anakinra/tocilizumab for the treatment of Adult-Onset Still’s Disease refractory to second-line therapy (adults). 6 July 2018. [cited 2019 Apr 28]. Available from: http://www.england.nhs.uk/publication/clinical-commissioning-policy-anakinra-tocilizumab-for-treatment-of-adult-onset-stills-disease-refractory-to-second-line-therapy-adults/.
   Google Scholar
• Ruscitti P, Cipriani P, Masedu F, et al. Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med. 2016;14:194.
   PubMed Web of Science ®Google Scholar
• Ichida H, Kawaguchi Y, Sugiura T, et al. Clinical manifestations of Adult-onset Still’s disease presenting with erosive arthritis: Association with low levels of ferritin and Interleukin-18. Arthritis Care Res (Hoboken). 2014;66:642–646.
   PubMed Web of Science ®Google Scholar
• Sfriso P, Priori R, Valesini G, et al. Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol. 2016;35:1683–1689.
   PubMed Web of Science ®Google Scholar
• Reiff A. Treatment of systemic juvenile idiopathic arthritis with tocilizumab - the role of anti-interleukin-6 therapy after a decade of treatment. Biol Ther. 2012;2:1.
   PubMedGoogle Scholar
• Galozzi P, Baggio C, Bindoli S, et al. Development and role in therapy of canakinumab in adult-onset Still’s disease. Front Pharmacol. 2018;9:1074.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin-1 inhibitors in 140 Italian Patients with adult-onset Still’s disease: a multicentre retrospective observational study. Front Pharmacol. 2017;8:369.
   PubMed Web of Science ®Google Scholar
• Mert A, Ozaras R, Tabak F, et al. Fever of unknown origin: a review of 20 patients with adult-onset Still’s disease. Clin Rheumatol. 2003;22:89–93.
   PubMed Web of Science ®Google Scholar
• Liu Z, Lv X, Tang G. Clinical features and prognosis of adult-onset Still’s disease: 75 cases from China. Int J Clin Exp Med. 2015;8:16634–16639.
   PubMed Web of Science ®Google Scholar
• Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol. 2010;22:561–566.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang Y, Bai Y, et al. Clinical characteristics and follow-up analysis of adult-onset Still’s disease complicated by hemophagocytic lymphohistiocytosis. Clin Rheumatol. 2016;35:1145–1151.
   PubMed Web of Science ®Google Scholar
• Vignes S, Wechsler B, Amoura Z, et al. Intravenous immunoglobulin in adult Still’s disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 1998;16:295–298.
   PubMed Web of Science ®Google Scholar
• Pirildar T. Treatment of adult-onset Still’s disease with leflunomide and chloroquine combination in two patients. Clin Rheumatol. 2003;22:157.
   PubMed Web of Science ®Google Scholar
• Ohe M, Oku K, Kono M, et al. Successful treatment with tacrolimus of refractory adult-onset Still’s disease. Korean J Intern Med. 2014;29:259–261.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease. J Rheumatol. 1999;26:373–378.
   PubMed Web of Science ®Google Scholar
• Yoo DH. Treatment of adult-onset still’s disease: up to date. Expert Rev Clin Immunol. 2017;13:849–866.
   PubMed Web of Science ®Google Scholar
• Segal R, Mozes E, Yaron M, et al. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum. 1989;32:370–377.
   PubMed Web of Science ®Google Scholar
• Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016;12:731–742.
   PubMed Web of Science ®Google Scholar
• Jung JH, Jun JB, Yoo DH, et al. High toxicity of sulfasalazine in adult-onset Still’s disease. Clin Exp Rheumatol. 2000;18:245–248.
   PubMed Web of Science ®Google Scholar
• Pouchot J, Arlet JB. Biological treatment in adult-onset Still’s disease. Best Pract Res Clin Rheumatol. 2012;26:477–487.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ursini F, Cipriani P, et al. Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13:1089–1097.
   PubMed Web of Science ®Google Scholar
• Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012;22:712–719.
   PubMed Web of Science ®Google Scholar
• Zhou S, Qiao J, Bai J, et al. Biological therapy of traditional therapy-resistant adult-onset Still’s disease: an evidence-based review. Ther Clin Risk Manag. 2018;14:167–171.
   PubMed Web of Science ®Google Scholar
• Junge G, Mason J, Feist E. Adult onset Still’s disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum. 2017;47:295–302.
   PubMed Web of Science ®Google Scholar
• Govoni M, Bortoluzzi A, Rossi D, et al. How I treat patients with adult onset Still’s disease in clinical practice. Autoimmun Rev. 2017;16:1016–1023.
   PubMed Web of Science ®Google Scholar
• Vitale A, Cavalli G, Colafrancesco S, et al. Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response. Front Pharmacol. 2019;10:296.
   PubMed Web of Science ®Google Scholar
• Cavagna L, Caporali R, Epis O, et al. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol. 2001;19:329–332.
   PubMed Web of Science ®Google Scholar
• Kraetsch HG, Antoni C, Kalden JR, et al. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis. 2001;60(Suppl 3):iii55–57.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Sibilia J, Mariette X, et al. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262–266.
   PubMed Web of Science ®Google Scholar
• Babacan T, Onat AM, Pehlivan Y, et al. Successful treatment of refractory adult Still’s disease and membranous glomerulonephritis with infliximab. Clin Rheumatol. 2010;29:423–426.
   PubMed Web of Science ®Google Scholar
• Dilhuydy MS, Vatan R, Etienne G, et al. Prolonged efficacy of infliximab for refractory adult-onset Still’s disease. Clin Exp Rheumatol. 2005;23:121–122.
   PubMed Web of Science ®Google Scholar
• Maeshima K, Ishii K, Iwakura M, et al. Adult-onset Still’s disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept. Mod Rheumatol. 2012;22:137–141.
   PubMed Web of Science ®Google Scholar
• Naniwa T, Tamechika S, Iwagaitsu S, et al. Successful use of higher-dose etanercept for multirefractory systemic flare of adult-onset still’s disease with liver failure with no response to tocilizumab therapy. Case Rep Rheumatol. 2013;2013:923497.
   PubMedGoogle Scholar
• Singh B, Biboa J, Musuku S, et al. Reversal of severe hepatitis with infliximab in adult-onset Still’s disease. Am J Med. 2013;126:e3–4.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017:76:51–57.
   Google Scholar
• Dayer JM, Oliviero F, Punzi L. A Brief History of IL-1 and IL-1 Ra in Rheumatology. Front Pharmacol. 2017;8:293.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54:2134–2144.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. van der Meer JW: Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25:469–484.
   PubMed Web of Science ®Google Scholar
• Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Dis. 2005;64:647–648.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Georgiou PE, Antonopoulos IA, et al. Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66:842–843.
   PubMed Web of Science ®Google Scholar
• Kötter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;37:189–197.
   PubMed Web of Science ®Google Scholar
• Mylona E, Golfinopoulou S, Samarkos M, et al. Acute hepatitis in adult Still’s disease during corticosteroid treatment successfully treated with anakinra. Clin Rheumatol. 2008;27:659–661.
   PubMed Web of Science ®Google Scholar
• Gesierich A, Stoevesandt J, Kneitz C, et al. Adult-onset Still’s disease: an uncommon differential diagnosis of urticaria and treatment with anakinra. J Eur Acad Dermatol Venereol. 2009;23:104–106.
   PubMed Web of Science ®Google Scholar
• Vordenbaumen S, Ostendorf B, Sander O, et al. Continuation of anakinra despite the development of a pruritic rash in an otherwise refractory case of adult-onset Still’s disease. Ann Rheum Dis. 2009;68:450–451.
   PubMed Web of Science ®Google Scholar
• Lahiri M, Teng GG. A case of refractory adult-onset Still’s disease treated with anakinra. Int J Rheum Dis. 2010;13:e36–41.
   PubMed Web of Science ®Google Scholar
• Fischer-Betz R, Specker C, Schneider M. Successful outcome of two pregnancies in patients with adult-onset Still’s disease treated with IL-1 receptor antagonist (anakinra). Clin Exp Rheumatol. 2011;29:1021–1023.
   PubMed Web of Science ®Google Scholar
• Yilmaz S, Cinar M, Simsek I, et al. Long-term efficacy and safety of Anakinra in a patient with liver transplant due to Adult onset Still’s Disease. Mod Rheumatol. 2014;24:1030–1031.
   PubMed Web of Science ®Google Scholar
• Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19.
   PubMed Web of Science ®Google Scholar
• Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52:1794–1803.
   PubMed Web of Science ®Google Scholar
• Nordstrom D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39:2008–2011.
   PubMed Web of Science ®Google Scholar
• Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther. 2014;8:2345–2357.
   PubMed Web of Science ®Google Scholar
• Nigrovic PA, Mannion M, Prince FH, et al.: Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011, 63:545–555.
   PubMed Web of Science ®Google Scholar
• Piel-Julian ML, Moulis G, Fournier P, et al. Early use of anakinra in adult-onset Still’s disease myocarditis. Scand J Rheumatol. 2018;47:511–512.
   PubMed Web of Science ®Google Scholar
• Schulert GS, Minoia F, Bohnsack J, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2018;70:409–419.
   PubMed Web of Science ®Google Scholar
• Yasin S, Schulert GS. Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment. Curr Opin Rheumatol. 2018;30:514–520.
   PubMed Web of Science ®Google Scholar
• Moulis G, Sailler L, Astudillo L, et al. May anakinra be used earlier in adult onset Still disease? Clin Rheumatol. 2010;29:1199–1200.
   PubMed Web of Science ®Google Scholar
• Taylor SA, Vittorio JM, Martinez M, et al. Anakinra-induced acute liver failure in an adolescent patient with Still’s disease. Pharmacotherapy. 2016;36:e1–4.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, De Vita S. Interleukin 1 receptor antagonist therapy-induced thrombocytopenia in adult onset Still’s disease. J Rheumatol. 2007;34:892–893.
   PubMed Web of Science ®Google Scholar
• Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still’s disease. Semin Arthritis Rheum. 2012;42:201–205.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–2406.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs. 2015;29:133–142.
   PubMed Web of Science ®Google Scholar
• Feist E, Quartier P, Fautrel B, et al. Efficacy and safety of canakinumab in patients with Still’s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018;36:668–675.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration, Center for Drug Evaluation and Research: Ilaris (canakinumab) injection. 23 September 2016. [ cited 2019 May 1]. Available from : http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125319Orig1s085,086,087Lbl.pdf
   Google Scholar
• Agency EM. EPAR summary for the public. Ilaris: INN canakinumab. Edited by; 2017.
   Google Scholar
• Henderson C, Goldbach-Mansky R. Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. Clin Immunol. 2010;135:210–222.
   PubMed Web of Science ®Google Scholar
• Petryna O, Cush JJ, Efthimiou P. IL-1 Trap rilonacept in refractory adult onset Still’s disease. Ann Rheum Dis. 2012;71:2056–2057.
   PubMed Web of Science ®Google Scholar
• Ilowite NT, Prather K, Lokhnygina Y, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:2570–2579.
   PubMed Web of Science ®Google Scholar
• Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68:1613–1617.
   PubMed Web of Science ®Google Scholar
• Terkeltaub RA, Schumacher HR, Carter JD, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther. 2013;15:R25.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58:2443–2452.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Spalding SJ, Hajj-Ali R, et al. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever. Biomed Res Int. 2014;2014:854842.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157:533–541.
   PubMed Web of Science ®Google Scholar
• Schumacher HR, Jr., Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64:876–884.
   PubMed Web of Science ®Google Scholar
• Schett G. Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford). 2018;57:ii43–ii50.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619–626.
   PubMedGoogle Scholar
• Scheinberg MA, Chapira E, Fernandes ML, et al. Interleukin 6: a possible marker of disease activity in adult onset Still’s disease. Clin Exp Rheumatol. 1996;14:653–655.
   PubMed Web of Science ®Google Scholar
• Hoshino T, Ohta A, Yang D, et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still’s disease. J Rheumatol. 1998;25:396–398.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–1167.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–997.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–1523.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Nara H, Hirata D, et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthritis Rheum. 2002;46:3388–3389.
   PubMed Web of Science ®Google Scholar
• Puechal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res (Hoboken). 2011;63:155–159.
   PubMed Web of Science ®Google Scholar
• Thonhofer R, Hiller M, Just H, et al. Treatment of refractory adult-onset Still’s disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int. 2011;31:1653–1656.
   PubMed Web of Science ®Google Scholar
• Sakai R, Nagasawa H, Nishi E, et al. Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports and literature review. Clin Rheumatol. 2012;31:569–574.
   PubMed Web of Science ®Google Scholar
• Andrade-Ortega L, Irazoque-Palazuelos F, Munoz-Lopez S, et al.: Efficacy of tocilizumab in refractory adult-onset Still’s disease; report of 2 cases. Reumatol Clin 2014, 10:199–200.
   PubMedGoogle Scholar
• Elkayam O, Jiries N, Dranitzki Z, et al. Tocilizumab in adult-onset Still’s disease: the Israeli experience. J Rheumatol. 2014;41:244–247.
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66:1659–1665.
   PubMed Web of Science ®Google Scholar
• Altinok G, Levine M, Dhar JP, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still’s disease. Case Rep Rheumatol. 2016;26:297–301.
   Google Scholar
• Bannai E, Yamashita H, Kaneko S, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still’s disease. Mod Rheumatol. 2016;26:297–301.
   PubMed Web of Science ®Google Scholar
• Li T, Gu L, Wang X, et al. A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease. Sci Rep. 2017;7:13477.
   PubMed Web of Science ®Google Scholar
• Ma Y, Wu M, Zhang X, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: A meta-analysis. Mod Rheumatol. 2018;28:849–857.
   PubMed Web of Science ®Google Scholar
• Watanabe E, Sugawara H, Yamashita T, et al. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still’s disease: a case-based review. Case Rep Med. 2016;2016:5656320.
   PubMed Web of Science ®Google Scholar
• Sumida K, Ubara Y, Hoshino J, et al. Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol. 2010;29:1191–1194.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Takahashi Y, Yamashita H, et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92–96.
   PubMed Web of Science ®Google Scholar
• Kadavath S, Zapantis E, Zolty R, et al. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still’s disease: targeting IL-6. Int J Rheum Dis. 2014;17:336–340.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Yamamura M, Taniai M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum. 2001;44:550–560.
   PubMed Web of Science ®Google Scholar
• Nagashima T, Iwamoto M, Matsumoto K, et al. Interleukin-18 in adult-onset Still’s disease: treatment target or disease activity indicator? Intern Med. 2012;51:449; author reply 451.
   Web of Science ®Google Scholar
• Yamashita T, Ishii A, Oda A, et al. Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Case Rep Med. 2016;55:2237–2247.
   Google Scholar
• Kawaguchi Y, Terajima H, Harigai M, et al. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still’s disease. Arthritis Rheum. 2001;44:1716–1717.
   PubMed Web of Science ®Google Scholar
• Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis. 2018;77:840–847.
   PubMed Web of Science ®Google Scholar
• Kiltz U, Kiefer D, Braun J, et al. Prolonged treatment with Tadekinig alfa in adult-onset Still’s disease. Ann Rheum Dis. 2018.
   Web of Science ®Google Scholar
• Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still’s disease. Clin Exp Rheumatol. 2010;28:265–267.
   PubMed Web of Science ®Google Scholar
• Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol. 2011;17:315–317.
   PubMed Web of Science ®Google Scholar
• Lee WS, Yoo WH. Rituximab for refractory adult-onset Still’s disease with thrombotic microangiopathy. Rheumatology (Oxford). 2014;53:1717–1718.
   PubMed Web of Science ®Google Scholar
• Ahmadi-Simab K, Lamprecht P, Jankowiak C, et al. Successful treatment of refractory adult onset Still’s disease with rituximab. Ann Rheum Dis. 2006;65:1117–1118.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865–876.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Mouy R, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015;67:2759–2770.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Rago C, Breda L, et al. Macrophage activation syndrome in Still’s disease: analysis of clinical characteristics and survival in paediatric and adult patients. Clin Rheumatol. 2017;36:2839–2845.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Grom AA, Behrens EM, et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13:289–298.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun. 2018;93:24–36.
   PubMed Web of Science ®Google Scholar
• Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145–159.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Minoia F, Davì S, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American college of rheumatology/Paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis. 2016;75:481–489.
   PubMed Web of Science ®Google Scholar
• Ahn SS, Yoo BW, Jung SM, et al. Application of the 2016 EULAR/ACR/PRINTO Classification Criteria for Macrophage Activation Syndrome in Patients with Adult-onset Still Disease. J Rheumatol. 2017;44:996–1003.
   PubMed Web of Science ®Google Scholar
• Tada Y, Inokuchi S, Maruyama A, et al. Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still’s disease? Rheumatol Int. 2019;39:97–104.
   PubMed Web of Science ®Google Scholar
• Kahn PJ, Cron RQ. Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol. 2013;40:743–744.
   PubMed Web of Science ®Google Scholar
• Savage E, Wazir T, Drake M, et al. Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still’s disease successfully treated with tocilizumab. Rheumatology (Oxford). 2014;53:1352–1353.
   PubMed Web of Science ®Google Scholar
• Tsuchida Y, Sumitomo S, Shoda H, et al. Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still’s disease. Mod Rheumatol. 2017;27:556–557.
   PubMed Web of Science ®Google Scholar
• Banse C, Vittecoq O, Benhamou Y, et al. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still’s disease. Joint Bone Spine. 2013;80:653–655.
   PubMed Web of Science ®Google Scholar
• Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still’s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol. 2007;25:758–759.
   PubMed Web of Science ®Google Scholar
• Tsuchida Y, Sumitomo S, Shoda H, et al. Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still’s disease. Mod Rheumatol. 2016;1–2.
   PubMed Web of Science ®Google Scholar
• Neel A, Wahbi A, Tessoulin B, et al. Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review. Crit Care. 2018;22:88.
   PubMed Web of Science ®Google Scholar
• Taams LS, Steel KJA, Srenathan U, et al. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14:453–466.
   PubMed Web of Science ®Google Scholar
• van Mens LJJ, van de Sande MGH, Menegatti S, et al. Brief report: interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses. Arthritis Rheumatol. 2018;70:1994–2002.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392:2441–2451.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–519.
   PubMed Web of Science ®Google Scholar
• Kubo S, Nakayamada S, Tanaka Y. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. Expert Rev Clin Immunol. 2019;15:1693–1700.
   PubMed Web of Science ®Google Scholar
• Tanaka Y. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. J Biochem. 2015;158:173–179.
   PubMed Web of Science ®Google Scholar
• Ladhari C, Jorgensen C, Pers YM. Treatment of refractory adult onset Still’s disease with combination anakinra and baricitinib therapy. Rheumatology (Oxford). 2019;58:736–737.
   PubMed Web of Science ®Google Scholar